To the Editor.
—Betaxolo hydrochloride, a β1 adrenergic receptor blocking agent, has a low incidence of systemic effects and has been shown to be clinically safe and effective for the treatment of glaucoma.1 However, a recent case report has documented respiratory problems with the use of topical betaxolo.2 We wish to report a case of reduction in pulmonary capacity following the use of topical betaxolol, as well as the failure of systemic therapy to alleviate symptoms, in a patient with minimal reactive airway disease.
Report of a Case.
—A 71-year-old woman had pseudoexfoliative glaucoma of the right eye. Ocular tensions in this eye ranged from 25 to 30 mm Hg. The optic disc had a cup-to-disc ratio of 0.9. A superior paracentral scotoma was present in the right eye. The left eye had a normal intraocular pressure, cup-to-disc ratio, and visual field. She was allergic to pilocarpine
Roholt PC. Betaxolol and Restrictive Airway Disease. Arch Ophthalmol. 1987;105(9):1172. doi:https://doi.org/10.1001/archopht.1987.01060090030011
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: